Evidence map›Paper›PMID 28003959›Full record

ArticleNeuroImage. Clinical2017

Use of T1-weighted/T2-weighted magnetic resonance ratio to elucidate changes due to amyloid β accumulation in cognitively normal subjects.

Fumihiko Yasuno, Hiroaki Kazui, Naomi Morita, Katsufumi Kajimoto, Masafumi Ihara, Akihiko Taguchi, Akihide Yamamoto, Kiwamu Matsuoka, Masato Takahashi, Jyoji Nakagawara and 3 more

Abstract read
In one paragraph

Article in NeuroImage. Clinical, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Fumihiko YasunoDepartment of Psychiatry, Nara Medical University, Kashihara, Japan; Department of Investigative Radiology, National Cerebral and Cardiovascular Center, Suita, Japan.
Hiroaki KazuiDepartment of Neuropsychiatry, Osaka University Medical School, Suita, Japan.
Naomi MoritaDepartment of Radiology, National Cerebral and Cardiovascular Center, Suita, Japan.
Katsufumi KajimotoDepartment of Neurology, National Cerebral and Cardiovascular Center, Suita, Japan.
Masafumi IharaDepartment of Neurology, National Cerebral and Cardiovascular Center, Suita, Japan.
Akihiko TaguchiDepartment of Regenerative Medicine Research, Institute of Biomedical Research and Innovation, Kobe, Japan.
Akihide YamamotoDepartment of Investigative Radiology, National Cerebral and Cardiovascular Center, Suita, Japan.
Kiwamu MatsuokaDepartment of Psychiatry, Nara Medical University, Kashihara, Japan.
Masato TakahashiDepartment of Psychiatry, Nara Medical University, Kashihara, Japan.
Jyoji NakagawaraDepartment of Radiology, National Cerebral and Cardiovascular Center, Suita, Japan.
Hidehiro IidaDepartment of Investigative Radiology, National Cerebral and Cardiovascular Center, Suita, Japan.
Toshifumi KishimotoDepartment of Psychiatry, Nara Medical University, Kashihara, Japan.
Kazuyuki NagatsukaDepartment of Neurology, National Cerebral and Cardiovascular Center, Suita, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The ratio of signal intensity in T1-weighted (T1w) and T2-weighted (T2w) magnetic resonance imaging (MRI) was recently proposed to enhance the sensitivity of detecting changes in disease-related signal intensity. The objective of this study was to test the effectiveness of T1w/T2w image ratios as an easily accessible biomarker for amyloid beta (Aβ) accumulation. We performed the T1w/T2w analysis in cognitively normal elderly individuals. We applied [

Indexed as

BenzothiazolesAgedAged, 80 and overAgingAlzheimer DiseaseAmyloid beta-PeptidesAniline CompoundsBiomarkersFemaleHumansImage Processing, Computer-AssistedMagnetic Resonance ImagingMaleMiddle AgedPositron-Emission TomographyThiazoles2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazoleAmyloid beta-PeptidesAniline CompoundsBenzothiazolesBiomarkersThiazoles11C–labeled Pittsburgh Compound B ([11C]PiB)AD, Alzheimer's diseaseAlzheimer's disease (AD)Amyloid-β (Aβ)Aβ, amyloid betaBP, binding potentialCSF, cerebrospinal fluidFWHM, full-width at half maximumMRI, magnetic resonance imagingPET, positron emission tomographyPiB-BPND, PiB-BP estimates relative to non-displaceable (ND) bindingPiB, Pittsburgh Compound BPositron emission tomography (PET)ROC, receiver operating characteristicT1-weighted/T2-weighted magnetic resonance ratio imagesT1w, T1-weightedT2w, T2-weightedVOI, volumes of interest

Identifiers

PMID28003959
PMCPMC5157788

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.